|Bid||386.72 x 1200|
|Ask||392.88 x 900|
|Day's Range||381.65 - 390.47|
|52 Week Range||223.25 - 468.55|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||20.14|
|Earnings Date||Jul 20, 2021 - Jul 26, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||405.41|
Biogen (BIIB) is developing its monoclonal antibody candidate, BIIB059, as a potential treatment for active systemic lupus erythematosus.
Investors know it's risky to bet against a dull market. But some S&P 500 stocks are starting to give investors a real thrill on the upside.
Earnings news boosted Adobe, Goldman Sachs broke technical support on the Dow Jones, and stocks fell into a quadruple witching session.